المؤلفون: Geurts BS; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Zeverijn LJ; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Leek LVM; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., van Berge Henegouwen JM; Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands., Hoes LR; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., van der Wijngaart H; Department of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.; Department of Internal Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands., van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., van de Haar J; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., van Ommen-Nijhof A; Department of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands., Kok M; Department of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, the Netherlands., Jansen AML; Department of Pathology, University Medical Cancer Center Utrecht, Utrecht, the Netherlands., de Leng WWJ; Department of Pathology, University Medical Cancer Center Utrecht, Utrecht, the Netherlands., de Jonge MJA; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands., Hoeben A; Department of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.; Department of Internal Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands., van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Westgeest HM; Department of Internal Medicine, Amphia Hospital, Breda, the Netherlands., Wessels LFA; Oncode Institute, Utrecht, the Netherlands.; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Voest EE; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Sep 03; Vol. 30 (17), pp. 3735-3746.

نوع المنشور: Clinical Trial; Journal Article; Multicenter Study

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Biomarkers, Tumor*/genetics , Mutation* , Neoplasms*/drug therapy , Neoplasms*/genetics , Neoplasms*/pathology , Neoplasms*/immunology , Whole Genome Sequencing*, Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Antineoplastic Agents, Immunological/therapeutic use ; Treatment Outcome

المؤلفون: Zeverijn LJ; Netherlands Cancer Institute, Amsterdam, Netherlands., Geurts BS; Netherlands Cancer Institute, Netherlands., Battaglia TW; Netherlands Cancer Institute, Amsterdam, Netherlands., van Berge Henegouwen JM; Erasmus MC, Rotterdam, Netherlands., de Wit GF; Netherlands Cancer Institute, Amsterdam, Netherlands., Hoes LR; Netherlands Cancer Institute, Amsterdam, Netherlands., van der Wijngaart H; Maastricht University Medical Centre, Netherlands., van der Noort V; Netherlands Cancer Institute, Amsterdam, Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, Netherlands., de Leng WWJ; University Medical Center Utrecht, Utrecht, Utrecht, Netherlands., Jansen AML; University Medical Center Utrecht, Utrecht, Utrecht, Netherlands., Chalabi M; Netherlands Cancer Institute, Amsterdam, Netherlands., van Herpen CML; Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands., Devriese LA; University Medical Center Utrecht Cancer Center, Utrecht, Netherlands., Erdkamp FLG; Zuyderland Medisch Centrum, Netherlands., Labots M; Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, Netherlands., de Jonge MJA; Erasmus MC Cancer Institute, Rotterdam, Netherlands., Kerver ED; Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands., Bins AD; Amsterdam UMC, Amsterdam, Netherlands., Leek LVM; Netherlands Cancer Institute, Amsterdam, Netherlands., Notohardjo JCL; Amsterdam UMC Location VUmc, Amsterdam, Netherlands., van den Eertwegh AJM; Amsterdam UMC, Netherlands., Wessels LFA; The Netherlands Cancer Institute, Amsterdam, NH, Netherlands., Verheul HMW; Erasmus MC, Rotterdam, Netherlands., Gelderblom H; Leiden University Medical Center, Leiden, Netherlands., van de Haar J; The Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands., Voest EE; Netherlands Cancer Institute, Amsterdam, Netherlands.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jul 18. Date of Electronic Publication: 2024 Jul 18.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

المؤلفون: Leek LVM; Department of Medical Oncology, Netherlands Cancer Institute, Antoni Van Leeuwenhoek, Amsterdam, The Netherlands., Notohardjo JCL; Department of Medical Oncology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands., de Joode K; Department of Medical Oncology and Radiology & Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands., Velker EL; Department of Medical Oncology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands., Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute, Antoni Van Leeuwenhoek, Amsterdam, The Netherlands., Suijkerbuijk KPM; Department of Medical Oncology, UMC Utrecht Cancer Center, Utrecht University, Utrecht, The Netherlands., Aarts MJB; Department of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands., de Groot JWB; Department of Medical Oncology, Oncology Center Isala, Isala, Zwolle, The Netherlands., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands., van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands., Westgeest HM; Department of Medical Oncology, Amphia Hospital, Breda, The Netherlands., de Gruijl TD; Department of Medical Oncology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands., Retel VP; Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek, Amsterdam, The Netherlands.; Health Technology and Services Research Department, Technical Medical Centre, University of Twente, Enschede, The Netherlands., Cuppen E; Hartwig Medical Foundation, Amsterdam, The Netherlands.; Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, Utrecht, The Netherlands., van der Veldt AAM; Department of Medical Oncology and Radiology & Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands., Labots M; Department of Medical Oncology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands., Voest EE; Department of Medical Oncology, Netherlands Cancer Institute, Antoni Van Leeuwenhoek, Amsterdam, The Netherlands., van de Haar J; Department of Medical Oncology, Netherlands Cancer Institute, Antoni Van Leeuwenhoek, Amsterdam, The Netherlands. j.vd.haar@nki.nl., van den Eertwegh AJM; Department of Medical Oncology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands. vandeneertwegh@amsterdamumc.nl.

المصدر: Scientific reports [Sci Rep] 2024 May 16; Vol. 14 (1), pp. 11244. Date of Electronic Publication: 2024 May 16.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

مواضيع طبية MeSH: Melanoma*/drug therapy , Melanoma*/pathology , Melanoma*/metabolism , Hypoalbuminemia* , Biomarkers, Tumor*/blood , Immune Checkpoint Inhibitors*/therapeutic use, Humans ; Female ; Male ; Middle Aged ; Aged ; Prognosis ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/metabolism ; Adult ; Neoplasm Metastasis ; L-Lactate Dehydrogenase/blood ; L-Lactate Dehydrogenase/metabolism ; Aged, 80 and over ; Multiomics

المؤلفون: Zeverijn LJ; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Looze EJ; Division of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Thavaneswaran S; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., van Berge Henegouwen JM; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Simes RJ; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Hoes LR; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Sjoquist KM; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., van der Wijngaart H; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands., Sebastian L; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Geurts BS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Lee CK; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., de Wit GF; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Espinoza D; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Roepman P; Hartwig Medical Foundation, Amsterdam, The Netherlands., Lin FP; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Jansen AML; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., de Leng WWJ; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., van der Noort V; Biometrics Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Leek LVM; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands., de Vos FYFL; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands., Thomas DM; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia., Voest EE; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.

المصدر: International journal of cancer [Int J Cancer] 2023 Oct 01; Vol. 153 (7), pp. 1413-1422. Date of Electronic Publication: 2023 Jul 10.

نوع المنشور: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms*/drug therapy , Breast Neoplasms*/drug therapy, Humans ; Female ; Cyclins ; Australia ; Precision Medicine ; Aminopyridines/therapeutic use ; Cyclin D ; Cyclin-Dependent Kinase 4 ; Protein Kinase Inhibitors/pharmacology ; Cyclin-Dependent Kinase 6 ; DNA Helicases ; Nuclear Proteins